ASMB

Assembly is a pre-commercial antiviral biotech — every dollar of its $72.3M FY2025 revenue (+153.5%) is collaboration/milestone income, not product sales, so the P/S of 6.1 and the narrowed net loss (-$6.12M vs. -$40.2M in FY2024) reflect lumpy partnership accounting rather than a durable earnings engine. The real signal is strategic: in December 2025 Gilead exercised its option to license the lead helicase-primase (HPI) herpes program, including ABI-1179 and ABI-5366. A partner of Gilead's caliber putting cash behind the lead asset is the single most important de-risking event here, and it shows up in the balance sheet — stockholders' equity jumped 519.8% to $207M, leverage is minimal at 0.25x liabilities/equity, and current assets of $255M dwarf $48.8M of current liabilities.

The counterweight is that this remains an early, binary pipeline story. Management's own 2025 highlights are all Phase 1a/1b interim readouts (1179, 5366, 4334, 6250) — encouraging, but years and multiple trials away from approval, and no new genital-herpes drug has cleared FDA/EU in over 25 years, underscoring the regulatory bar. Operating cash flow was -$41.1M against just $58.5M of cash; even with the larger current-asset base, the company burns aggressively (R&D $64.8M) and share count already ballooned 111.4%, so dilution or further partnering is a when-not-if. The accumulated deficit of -$832M is the honest scorecard of a company that has never turned a profit.